Our current technology allows us to isolate and store the intestinal microbiota in viable conditions, to ensure the exact same composition, diversity and functionality.

The technology development of Microviable Therapeutics is based on an awarded patent (P201630176) and the optimization on internal protocols that allowed us to bring GutAlive to the market offering associate services for microbiota analyses and microbiota storage in viable conditions.

These goals constitute the basis of this science-based biotech, opening new avenues for further development of next generation biotherapeutics based on complex communities of microbes from the intestinal microbiota to improve human health.


We are currently developing our pipeline of next generation biotherapeutics for several diseases